Sino Biopharmaceut (SBMFF) Stock Rating Upgraded by Zacks Investment Research
Sino Biopharmaceut (OTCMKTS:SBMFF) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report released on Friday. The firm currently has a $2.00 price target on the stock. Zacks Investment Research‘s target price would suggest a potential upside of 3.90% from the company’s previous close.
According to Zacks, “Sino Biopharmaceutical Limited researches, develops, produces and sells biopharmaceutical products for the medical treatment of ophthalmia, as well as modernized Chinese medicine and chemical medicine for the treatment of hepatitis. Sino Biopharmaceutical Limited is headquartered in Wanchai, Hong Kong. “
Shares of Sino Biopharmaceut (SBMFF) traded up $0.13 on Friday, reaching $1.93. The company’s stock had a trading volume of 51,000 shares, compared to its average volume of 21,916. Sino Biopharmaceut has a fifty-two week low of $0.72 and a fifty-two week high of $1.98.
Sino Biopharmaceutical Limited, researches, develops, manufactures, and markets Chinese medicines and chemical medicines in Hong Kong. The company operates through three segments: Modernized Chinese Medicines and Chemical Medicines, Investment, and Others. Its principal products include hepatitis medicines, such as Tianqingganmei injections, Runzhong dispersible tablets, Mingzheng capsules, Tianqingganping enteric capsules, and Ganlixin injections and capsules; and cardio-cerebral medicines comprising Yilunping and Tuotuo tablets, as well as Tianqingning injections; and oncology medicines consisting of Zhiruo, Saiweijian, and Tianqingyitai injections.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sino Biopharmaceut Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sino Biopharmaceut and related companies with MarketBeat.com's FREE daily email newsletter.